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ABSTRACT
Objectives: The objective of this study is to determine the prevalence of Chlamydia trachomatis and
risk factors for positive repeat tests in a high-risk population presenting for early prenatal care.
Methods: We completed a retrospective cohort study of 2,484 women who initiated prenatal care
prior to 20 weeks gestation, delivered, and received testing for cervical C. trachomatis at Grady
Memorial Hospital or a Grady-affiliated clinic between July 1, 1993 and Deeember 31, 1994. We
calculated adjusted odds ratios (OR) for selected risk factors for a positive initial test and for a
positive subsequent test after an initial negative test.
Results: The prevalence of C. trachomatis was 14.8%. At initial testing, 10.4% of the women were
positive. If the initial test was negative, 5.7% had a positive subsequent test; but if the initial test was
positive, 32.0% had a positive subsequent test (P<0.001). The variables significantly and indepen-
dently associated with a positive initial test were black raee/ethnieity, age less than 25, unmarried,
and less than a high-school education (adjusted OR of 1.66, 3.53, 2.18, and 1.81, respectively).
Variables significantly and independently associated with a positive subsequent test after a negative
initial test were white race/ethnieity, black race/ethnicity, age less than 25, and less than a high-
school education (adjusted OR 8.69, 7.77, 4.12,and 2.27, respectively).
Conclusions: In our inner-city population, most pregnant women have risk factors suggesting the
need to rescreen for C. trachomatis in the second half of pregnancy. Infect. Dis. Obstet. Gynecol.
6:116-122, 1998. (C) 1998 Wiley-Lass, Inc.
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hplamydia
trachomatis is the most common, re-
ortable sexually transmitted disease in the
United States. It is estimated that of sexually ac-
tive women, 4%-5% are currently infected with
this organism, z In pregnant women, the prevalence
of C. trachomatis ranges from 2%-30%.3-s Risk fac-
tors for acquiring C. trachomatis include multiple
sex partners, a new sexual partner in the preceding
three months, young age (<25 years), unmarried
status, low parity, nonbarrier contraception, low so-
cioeconomic status, receiving care at public health
clinics, nonwhite race, and past history or presence
of other sexually transmitted diseases.3-6
The obstetric significance of C. trachomatis cer-
vical infection has been well-studied. The pres-
ence of this organism has been associated with the
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perinatal complications of premature rupture of
membranes (PROM), preterm labor and birth, low
birth weight, intrauterine growth retardation, still-
birth, and postpartum and postabortal endometri-
tis.3,7-1s Following passage through an infected
birth canal, an infant has considerable risk of ac-
quiring C. trachomatis. An infant delivered to a
woman infected with this organism present in the
cervix risks acquiring pneumonitis, (3%-18%), con-
junctivitis (18%-50%), and nasopharyngeal infec-
tion (15%-20%). 16-e3 Treatment of C. trachomatis
infection during pregnancy can decrease substan-
tially the development of these maternal and peri-
natal complications,e It is, therefore, important to
identify women with C. trachomatis infection during
pregnancy.
Because of these maternal and perinatal risks,
the Centers for Disease Control (CDC) recom-
mends screening for C. trachomatis cervical infec-
tion at the first prenatal visit for all pregnant
women, whereas the American College of Obste-
tricians and Gynecologists (ACOG) does not rec-
ommend universal screening. 1,s Both the CDC and
ACOG recommend screening in the third trimester
for patients at high risk, although no data are cited
to support this recommendation.
At Grady Memorial Hospital in Atlanta, Georgia,
the current obstetric policy regarding C. trachomatis
is to screen all women routinely for cervical infec-
tion at their first prenatal visit and to repeat testing
at 34 to 36 weeks gestation. A woman is also re-
tested if she presents with preterm labor, preterm
PROM, or signs and symptoms of cervical infec-
tion. This study investigates the prevalence of
positive C. trachomatis tests and rate of positive re-
peat tests throughout gestation in a high-risk popu-
lation presenting for early prenatal care. In addi-
tion, the researchers sought to identify specific risk
factors that would suggest a benefit for repeat
screening among those gravidas with negative ini-
tial screening.
SUBJECTS AND METHODS
Grady Memorial Hospital cares primarily for indi-
gent patients of Fulton and DeKalb counties,
which encompass most of the Atlanta metropolitan
area. It also serves as a referral center for patients
with complications in metropolitan Atlanta and
eight surrounding counties.
Women considered for this study were all those
who initiated prenatal care, delivered, and received
testing for cervical C. trachomatis infection at Grady
Memorial Hospital or a Grady-affiliated clinic dur-
ing the 18-month period from July 1, 1993, through
December 31, 1994. Since we were attempting to
determine the utility of repeat testing, only pa-
tients presenting for prenatal care at less than 20
weeks gestation were included. After study of this
initial group, subsequent analysis was confined to
the women who actually had follow-up C. tracho-
matis tests later in pregnancy. Cervical C. trachoma-
tis screens were performed exclusively with Gen-
Probe (Gen-Probe Incorporated, San Diego, CA)
from July 1993 through October 1993. After Octo-
ber 1993, MicroTrak II Chlamydia EIA (Syva Com-
pany, San Jose, CA) was primarily used. Patients
were treated without confirmatory C. trachomatis
cultures. At the time of the study, the majority of
patients were treated, according to the current
CDC recommendations, with oral erythromycin in
split doses (1 gram/day for 2 weeks or 2 grams/day
for week). If allergy to erythromycin was claimed
or if intolerance was demonstrated, patients were
treated with amoxicillin (500mg, three times daily
for one week). All screening tests were performed
in Grady Memorial Hospital’s laboratory and were
entered into a mainframe computer database.
Evaluation of that database allowed identification
of all women tested for cervical C. trachomatis in-
fection during the study, the date of each test, and
the result of each test.
A separate obstetric database is maintained, into
which is entered an extensive demographic and
medical review of all patients delivered at Grady
Memorial Hospital. This obstetric database, which
is completed at delivery, includes date of delivery,
gestational age at delivery, and selected historical
information. Cross-referencing these two distinct
databases allowed evaluation of the gestational age
at which each test was performed, the number of
tests performed on each patient, the result of each
test, and the presence of specific demographic and
historical variables. If more than one subsequent C.
trachomatis test was done, any subsequent positive
was considered a positive repeat test, so long as
that test was performed more than two weeks after
the first; this interval was to allow for success of
initial drug therapy. Although it was the policy to
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treat the sexual partners of those who tested posi-
tive or to refer them for treatment, compliance with
this recommendation is not recorded on the data-
base. The relative risk (RR) and adjusted ORs of
each variable were determined, with 95% confi-
dence intervals (CI), for a positive initial test and a
positive subsequent test after an negative initial
test, by the use of the EPI INFO (CDC, Atlanta,
GA) statistical program for univariate and the SPSS
(SPSS Inc., Chicago, IL) statistical program for
multivariate analysis. Patients who had repeat test-
ing after an negative initial test were compared
with patients who did not have repeat testing for
the same, previously mentioned variables.
RESULTS
During the study period, 2,484 women presented
for prenatal care prior to 20 weeks gestation and
had at least one C. trachomatis screening test. On
these 2,484 prenatal patients, 5,745 C. trachomatis
tests were performed (1 to 11 tests per patient, with
a mean of 2.5). Of these patients, 259 (10.4%) had
a positive initial test, 2,225 (89.6%) had a negative
initial test, and 2,173 (87.5%) had at least one sub-
sequent test. Of the 2,484 patients meeting criteria
for initial inclusion, 368 had at least one positive
test during pregnancy, for a prevalence of 14.8%
during pregnancy.
Of the 2,225 patients who initially tested nega-
tive for C. trachomatis, 296 (13.3%) had no further
testing, whereas 1,929 (86.7%) had follow-up test-
ing. Of these 1,929 patients, 109 (5.7%) subse-
quently had a positive test, and 1,820 (94.3%) had
negative follow-up tests. Of the 259 patients who
had a positive initial test, 15 (5.8%) were tested
only once, but 244 (94.2%) had follow-up testing.
Of these 244 patients, 78 (32.0%) had a recurrent
positive test during that pregnancy. The percent-
age of patients who had a subsequent positive test
after an initial positive test is significantly higher
than the percentage of patients who had a subse-
quent positive test after an initial negative test
(32.0% vs. 5.7%, P < 0.001; RR 5.66, 95% CI 4.37-
7.33.
Selected risk factors for a positive initial test
were assessed. Risk factors independently associ-
ated with a positive initial test for C. trachomatis
during pregnancy were found to be black race
(compared to "other," which was primarily His-
panic), age less than 25, unmarried status, and less
than a high-school education (Table 1).
To determine if health care providers were se-
lectively retesting patients based On demographic
or historical risk factors, patients who initially
tested negative for C. trachomatis and had only one
test prior to 20 weeks gestation were compared to
patients who initially had a negative test and had
repeat screening. Patients who were significantly
more likely to have had repeat screening included
those who were less than 25 years old (RR 1.05,
95% CI 1.01-1.08), nulligravid (RR 1.04, 95% CI
1.01-1.08), and had no prior abortions (RR1.04,
95% CI 1.01-1.08).
Patients who initially tested negative and had
only negative repeat testing were then compared to
those who had at least one positive subsequent
test. Risk factors independently associated with a
positive subsequent test after a negative initial test
were of white or black race (compared to "other"),
were younger than 25 years, and had less than a
high-school education (Table 2).
COMMENT
To our knowledge, this is the first study to evaluate
the clinical utility of repeated C. trachomatis testing
in pregnancy. The CDC and ACOG recommend
follow-up testing in the third trimester for patients
who are at high risk; however, no data are cited. We
designed our study to determine whether we could
target a high-risk segment of our population for
whom subsequent testing would be most efficient.
As a cost-saving measure, we had hoped to identify
patients for whom subsequent testing could be
safely omitted.
The prevalence of a positive, nonculture C. tra-
chomatis test at the first prenatal visit was 10.4%,
and the overall prevalence during pregnancy was
14.8% in our population. This prevalence is similar
to previously published reports.
3 Patients with a
positive initial test were at significantly higher risk
for a positive subsequent test (32.0%) than patients
who initially tested negative (5.7%). This finding
supports retesting patients who are positive ini-
tially, because they are at high risk for reinfection
or failed treatment. A weakness of this study’s de-
sign is that in patients with positive subsequent
tests, we were unable to distinguish between rein-
fection and failed treatment. Although we ex-
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TABLE I. Risk factors associated with a positive initial C. trachomatis test during pregnancy
Positive Percent RR
Risk factor* test positive (95% CI)
Adjusted OR
(95% CI)
Race/ethnicity (n 2484)
Black (n 1827) 221 12.1
White (n 91) 6 6.6
Other (n 566) 32 5.7
Age (n 2484)
<25 (n 1455) 219 5.
->25 (n 1029) 40 3.9
Marital status (n 2484)
Not currently married (n 1805) 230 12.7
Married (n 679) 29 4.3
Education (n 2461)
< High school (n 689) 96 13.9
High school (n 1722) 156 9.
Gravidity (n 2484)
Nulligravid (n 820) 117 14.3
At least one pregnancy (n 1664)
History of preterm (n 2484)
Prior preterm (n 253)
142 8.5
2.5 9.9
234 10.5 No preterm (n 223 I)
History of abortion (n 2484)
No prior abortion (n 1600)
Prior abortion (n 884) 68 7.7
Drug use (n 2484)
Drug use (n 99) 9 10.5
No drug use (n 2385) 250 9.
Alcohol use (n 2483)
Alcohol use (n 2246) 237 10.6
No alcohol use (n 237)
Contraception (n 2442)
None of nonbarrier (n 2083)
22 9.3
202 9.7
53 14.8 Condom (n 359)
2.14
(I.49-3.06)
1.17
(0.50-2.71)
1.00
3.87
(2.79-5.37)
1.00
2.98
(2.05-4.35)
1.00
1.53
(I.21-1.94)
1.00
1.67
(I.33-2.10)
1.00
0.94
(0.64-1.39)
1.00
1.55
(I.21-2.20)
1.00
0.87
(0.46-1.63)
1.00
0.88
(0.58-I .33)
1.00
0.66
(0.50-0.87)
1.00
1.66
(I.0 I-2.74)
0.95
(0.35-2.62)
1.00
3.53
(2.44-5.09)
1.00
2.18
(1.32-3.59)
1.00
1.81
(I.34-2.46)
1.00
0.71
(O.S i-.O0)
1.00
RR, relative risk; OR, odds ratio; CI, confidence interval.
*n 2484 unless specific item on obstetric data base left blank.
**Variable excluded from model using multivariate logistic regression with stepwise backward elimination.
cluded tests repeated within two weeks of an initial
test in this analysis, tests of cures may have been
performed outside this window of time. There was
no specific policy in place recommending a test of
cure. Therefore, this practice was likely to vary by
provider.
Only 87.5% of our patients had repeat screening
during pregnancy, although such screening is the
official policy at our institution. There are several
possible explanations for this discrepancy. Patients
may have delivered prior to the recommended ges-
tational age of repeat testing (34-36 weeks) or may
have been noncompliant with clinic visits and may
have delivered before returning to the clinic. Fi-
nally, individual practitioners may have indepen-
dently not retested patients whom they considered
to be at low risk. There does not seem to be a
clinically significant trend among our practitioners
to target certain groups for repeat testing.
We found that there exist in our population cer-
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TABLE 2. Risk factors associated with a positive subsequent C. trachomatis test during pregnancy after a
negative initial test
Positive Percent RR
Risk factor* test positive (95% CI)
Adjusted OR
(95% CI)
Race/ethnicity (n 1929)
Black (n 1397) 100 7.2
White (n 70) 4 5.7
Other (n 462) 5 I.
Age (n 1929)
<25 (n 1093) 95 8.7
->25 (n 836) 14 1.7
Marital status (n 1929)
Not currently married (n 1370) 100 7.3
Married (n 559) 9 1.6
Education (n 191 I)
< High school (n 519) 41 7.9
High school (n 1392) 68 4.9
Gravidity (n 1929)
Nulligravid (n 627) 45 7.2
At least one pregnancy (n 1302)
History of preterm (n 1929)
Prior preterm (n 192)
No preterm (n 1737)
History of abortion (n 1929)
No prior abortion (n 1241)
64 4.9
8 4.2
101 5.8
70 5.6
Prior abortion (n 688) 39 5.7
Drug use (n 1929)
Drug use (n 71) 3 4.2
No drug use (n 1858) 106 5.7
Alcohol use (n 1929)
Alcohol use (n 180) 6 3.3
No alcohol use (n 1749)
Contraception (n 1897)
None or nonbarrier (n 1626)
Condom (n 271)
103 5.9
85 5.2
23 8.5
6.61
(2.71-16.14)
5.28
(I.45-19.19)
1.00
5.19
(2.83-9.03)
1.00
4.53
(2.13-8.40)
1.00
1.62
(. -:.35)
1.00
1.45
(.00-2. O)
1.00
0.72
(0.35-1.45)
1.00
1.0
(0.65-1.52)
1.00
0.74
(0.24-2.28)
1.00
0.57
(0.25-t .27)
1.00
0.62
(0.40-0.96)
1.00
7.77
(2.51-24.0)
8.69
(2.00-37.7)
1.00
4.12
(2.29-7.42)
1.00
2.08
(0.91-4.72)
1.00
2.27
(I.47-3.52)
1.00
RR, relative risk; OR, odds ratio; CI, confidence interval.
*n 1929 unless specific item on obstetric data base left blank.
**Variable excluded from model using multivariate logistic regression with stepwise backward elimination.
tain groups that are at high risk for having a positive
subsequent C. trachomatis test after a negative ini-
tial test. This may be secondary to new-onset in-
fection in pregnancy or due to a false-negative ini-
tial test, since the sensitivity of the screening tests
used is less than 100%.24 Factors that were found to
be independently associated with a positive subse-
quent test after a negative initial test were similar
to the risk factors for a positive initial test and in-
clude black race or ethnicity, age less than 25, un-
married status, and less than a high-school educa-
tion. In our population, we found that white pa-
tients were significantly more likely to have a
positive repeat test than those designated nonblack
and nonwhite (primarily Hispanic), although
whites were no more likely to have a positive initial
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test. Although often cited as a risk factor for C.
trachomatis,3-6 a history of sexually transmitted dis-
ease prior to pregnancy was unable to be deter-
mined from the database.
There were several limitations to this .study.
The true incidence of C. trachomatis infection in
our population is unknown because tissue culture
for C. trachomatis (which was considered the gold
standard) was not available at Grady Memorial
Hospital. Although having a positive C. trachomatis
test makes an individual highly likely to have a C.
trachomatis infection, the positive predictive value
of a test will vary among populations. Another limi-
tation to this study is the inability to extrapolate
these results to other populations. The demo-
graphic and historical risk factors identified in this
study may not be valid in a nonindigent population
or in women who do not present for prenatal care.
In conclusion, this study suggests that in a high-
risk, indigent, obstetric population there exist sub-
groups of patients who are at increased risk for C.
trachomatis infection. It is important to identify
these patients, because many of the potentially ad-
verse maternal and fetal outcomes associated with
C. trachomatis can be prevented by antepartum
screening and treatment,z3 Women in our popula-
tion who should be retested for C. trachomatis in
pregnancy include at least those who initially test
positive, are less than 25 years old, are black or
white, and have less than a high school education.
The testing of women without any of the above
risk factors should be based on clinical judgment.
Further studies are necessary to identify women
who do not need to be retested, to determine the
optimal frequency and gestational age for testing,
to determine the cost and efficacy of repeat screen-
ing, and to determine whether repeat screening im-
proves maternal or fetal outcome.
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